Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

US Drug Company Founder Gets Three Years in Prison

By Pharmaceutical Processing | May 12, 2014

ALEXANDRIA, Virginia (AP) — A Virginia-based drug company was ordered Friday to pay $3.4 million and its founder sentenced to three years in prison for distributing thousands of units of misbranded drugs to doctors across the U.S.

Gallant Pharma International Inc. and its co-owner, 39-year-old Syed “Farhan” Huda of Arlington, pleaded guilty last year in federal court in Alexandria to illegal importation and introducing misbranded drugs into interstate commerce.

According to court documents, the company made $3.4 million in profits between 2009 and 2013 by illegally importing chemotherapy and cosmetic surgery drugs, in violation of the Food and Drug Administration’s regulatory scheme.

Prosecutors say the drugs were shipped from countries including Turkey and Switzerland, in ways that compromised their safety, including a lack of temperature controls for drugs that need to be kept cool to maintain their efficacy.

Huda’s lawyer, Mark Schamel, argued for a lighter sentence, arguing in part that the drugs received by doctors and patients were never “adulterated or problematic in any way.” He also noted in court papers that the crime occurred in the context of a regulatory environment where U.S. patients are forced to pay much higher drug prices than the rest of the world.

“A more cynical person might argue that the crime that was perpetrated here was against the citizens of the United States who are paying two and three times the price for the same pharmaceuticals Canadians, EU patients and others across the world are paying,” Schamel wrote in court papers.

Twelve people have been convicted in connection with the prosecution.

Related Articles Read More >

FDA logo
FDA prevented 317 drug shortages in 2021
Pfizer-BioNTech vaccine vial
Pfizer, BioNTech moving forward on seeking COVID-19 vaccine EUA for youngest children
FDA logo
FDA curtails use of Janssen COVID-19 vaccine over blood clotting concerns
FDA logo
FDA sends warning letters to CBD and delta-8 THC product vendors

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards